Granules India has announced a planned investment of approximately ₹2,000 crore over the next three to four years. This substantial investment signals a significant shift in Hyderabad's pharmaceutical sector, as reported by Urban Acres.
This investment is more than just a corporate expansion; it indicates a change in the company's business model. Urban Acres states that Granules India is moving from high-volume generic medicines towards complex generics, oncology products, peptide contract development and manufacturing, and technology-enabled production.
For Hyderabad's industrial economy, this proposed investment highlights the continuing importance of specialized manufacturing capacity, research infrastructure, and global market access, according to Urban Acres.
The company's Chief Financial Officer, Mukesh Surana, stated that the capital expenditure will be directed towards complex generics, oncology, peptide CDMO, United States operations, manufacturing capacity, research and development infrastructure, digitalization, artificial intelligence-led manufacturing excellence, and quality systems, Urban Acres reported.
This plan was discussed at an investor webinar, the transcript of which was submitted to the stock exchanges and reported by Times of India – Hyderabad, as noted by Urban Acres.
This investment is significant for readers in Andhra Pradesh and Telangana as it could create new job opportunities and foster economic growth within the pharmaceutical sector in Hyderabad, benefiting the regional economy.
